Matthieu Bosman

The TAK1-NF-κB axis as therapeutic target for AML

Matthieu Bosman, Hein Schepers, Jennifer Jaques et al. · Blood · 2014 · 60 citations · Full text

Medicine, Cancer Biology, Oncology +11

Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1

Matthieu Bosman, Jan Jacob Schuringa, Edo Vellenga · Experimental Hematology · 2013 · 29 citations

Medicine, Oncology, Pharmacology +14

Decreased Affinity of Recombinant Human Tumor Necrosis Factor-related Apoptosis-inducing Ligand (rhTRAIL) D269H/E195R to Osteoprotegerin (OPG) Overcomes TRAIL Resistance Mediated by the Bone Microenvironment

Matthieu Bosman, Carlos R. Reis, Jan Jacob Schuringa et al. · Journal of Biological Chemistry · 2013 · 17 citations · Full text

Life Sciences, Oncology, Pharmacology +14

BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells

Marco Carretta, Annet Z. Brouwers-Vos, Matthieu Bosman et al. · PLoS ONE · 2017 · 15 citations · Full text

Life Sciences, Molecular Biology, Oncology +17